These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31505986)

  • 1. Adaptive clinical endpoint bioequivalence studies with sample size re-estimation based on a nuisance parameter.
    Zhu L; Sun W
    J Biopharm Stat; 2019; 29(5):776-799. PubMed ID: 31505986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for equivalence assessment with multiple endpoints.
    Sun A; Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive designs for IVPT data with mixed scaled average bioequivalence.
    Lim D; Rantou E; Kim J; Choi S; Choi NH; Grosser S
    Pharm Stat; 2023; 22(6):1116-1134. PubMed ID: 37555542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses.
    Tsai CA; Huang CY; Liu JP
    Stat Med; 2014 Aug; 33(19):3300-17. PubMed ID: 24771655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.
    Hade EM; Young GS; Love RR
    Trials; 2019 Aug; 20(1):527. PubMed ID: 31443726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods and applications of percentile estimation.
    Xia Q; Tsong Y; Weng YT
    J Biopharm Stat; 2020 Mar; 30(2):267-276. PubMed ID: 31237475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.